Browsing: oral

Researchers at the Fralin Biomedical Research Institute at VTC have developed an experimental oral therapy that protected mice from otherwise harmful radiation exposure while preserving radiation’s ability to destroy cancer cells, a finding that could ultimately improve cancer treatment and strengthen preparedness for radiological emergencies

An oral small molecule that increases energy expenditure rather than suppressing appetite produced substantial weight loss while preserving lean mass in mouse models of obesity, suggesting a potentially complementary strategy to GLP-1–based therapies

The Medicines and Healthcare products Regulatory Agency confirmed on 10 August that it had authorised orforglipron, sold under the brand name Foundayo, making Britain the first country in Europe to licence an oral GLP-1 receptor agonist for both weight management and type 2 diabetes. Julian Beach, the MHRA’s executive director of healthcare quality and access,…

The GHA is considering whether to offer oral GLP-1 weight-loss drugs, with the service expected to change significantly within the next decade as new treatments become available, the Director of Public Health, Dr Helen Carter, has said

The article explains how preventive dental care supports healthy gums and contributes to lifelong overall wellness

It’s already been a full commercial quarter since the April approval of Eli Lilly’s weight loss pill Foundayo—which means analysts now have around three months’ worth of sales data to see how the oral obesity battle is shaping up

Rani TherapeuticsNASDAQ: RANI outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity

VCT220 is a novel nonpeptide, orally available glucagon-like peptide-1 receptor agonist (GLP-1RA) designed to reduce the complex administration of injectable GLP-1RAs and the limited bioavailability of on-marketing oral agents for obesity care. We conducted a multicenter, randomized, double-blind, placebo-controlled, phase II trial (Registration no. CTR20233978 and NCT06569355) across 13 sites in China. Adults aged 18–75…

According to a 2025 poll by KFF (formerly known as the Kaiser Family Foundation), one in eight adults in the U.S. is taking a GLP-1 drug. These medications — the most recognizable are Ozempic® and Wegovy® — were used initially to treat type 2 diabetes, but are now widely used, along with lifestyle and dietary…

MedPal AI plc (AIM: MPAL)has highlighted the UK approval of Eli Lilly’s once-daily oral GLP-1 treatment, Foundayo, which has been authorised for weight loss and weight maintenance in eligible adults